Arcturus signs $80M collaboration with Thermo Fisher for ARCT-032 CF program

Arcturus Therapeutics Holdings Inc.

Thermo Fisher to provide up to $40M in clinical manufacturing services; Arcturus to spend up to $40M on CRO services via PPD.
Collaboration supports Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
Upon regulatory approval, Thermo Fisher receives exclusive commercial manufacturing rights for ARCT-032.
Agreement includes technical transfer, clinical trial materials, PPQ batches, and stability studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.